BDF
GYRE icon

Black Diamond Financial’s Gyre Therapeutics GYRE Stock Holding History

Black Diamond Financial’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,400
Closed -$32K – 105
2022
Q2 		$32K Hold
2,400
– – 0.01% 112
2022
Q1 		$12K Hold
2,400
– – ﹤0.01% 125
2021
Q4 		$16K Sell
2,400
-3,200
-57% -$54.7K 0.01% 95
2021
Q3 		$173K Hold
5,600
– – 0.08% 74
2021
Q2 		$182K Buy
5,600
+533
+11% +$18.3K 0.07% 83
2021
Q1 		$192K Buy
+5,067
New +$232K 0.08% 81

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Black Diamond Financial's GYRE Position: Q3 2022 in Review

Black Diamond Financial sold out of Gyre Therapeutics (GYRE) in Q3 2022, closing a stake of 2,400 shares — an estimated $32K sold.

Black Diamond Financial first reported a position in GYRE in Q1 2021 and held it in 6 quarters. The position peaked at $192K in Q1 2021. 35 funds tracked by Wall St. Rank hold GYRE as of Q3 2022.

  • Black Diamond Financial reported no remaining Gyre Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Black Diamond Financial sold 2,400 Gyre Therapeutics shares in Q3 2022, an estimated $32K.
  • Black Diamond Financial first reported a position in Gyre Therapeutics in Q1 2021 and held it in 6 quarters.
  • Black Diamond Financial's Gyre Therapeutics position peaked at $192K in Q1 2021.
  • 35 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2022.

Based on Black Diamond Financial's 13F filing for Q3 2022, filed 9 Nov 2022.